Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glyburide
Drug ID BADD_D01030
Description Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].[L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]
Indications and Usage Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.
Marketing Status Prescription; Discontinued
ATC Code A10BB01
DrugBank ID DB01016
KEGG ID D00336
MeSH ID D005905
PubChem ID 3488
TTD Drug ID D05LYX
NDC Product Code 63187-667; 75834-204; 68071-5215; 63629-1393; 66267-103; 70934-855; 70934-409; 52817-121; 75834-203; 65862-318; 68382-656; 71209-009; 70934-715; 0093-9477; 0093-8344; 65862-029; 0121-0930; 0009-0352; 68382-657; 12579-056; 50090-3429; 0143-9920; 72241-040; 55289-606; 70518-1513; 0121-0931; 76333-155; 23155-056; 0115-1744; 53002-4170; 68382-658; 63629-2907; 65841-833; 12579-054; 68071-2589; 46438-0059; 68071-4142; 61919-330; 68071-4730; 0093-8343; 0009-3449; 65862-030; 68788-7970; 71335-0150; 42291-317; 0143-9918; 76333-154; 68071-2402; 63187-848; 50090-0495; 0143-9919; 55700-725; 0115-1742; 0093-8036; 72241-039; 0093-8035; 72241-038; 68071-5217; 0093-8342; 49452-3355; 23155-057; 52817-120; 71209-011; 70518-2695; 42291-316; 0121-0929; 65841-834; 43063-433; 70518-1646; 0093-9433; 68071-4695; 70934-569; 52817-122; 65862-028; 62147-0002; 63187-659; 50090-0494; 68071-5029; 68071-5030; 0093-8034; 50090-4215; 12828-0066; 71209-010; 61919-378; 0115-1743; 0093-9364; 50090-5776; 65841-832; 76333-156; 71335-0069; 70518-2644; 70518-1201; 12579-055; 43353-656; 75834-202; 43353-659; 0009-0341; 23155-058; 65691-0041
Synonyms Glyburide | Glybenclamide | Glibenclamide | Diabeta | Euglucon 5 | Neogluconin | HB-419 | HB 419 | HB419 | HB-420 | HB 420 | HB420 | Maninil | Micronase | Daonil | Euglucon N
Chemical Information
Molecular Formula C23H28ClN3O5S
CAS Registry Number 10238-21-8
SMILES COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HaemolysisGlucose-6-phosphate 1-dehydrogenaseP11413T634848562390; 15126005; 2502894; 12610074; 15645702; 1760119; 3603644
ObesityATP-binding cassette sub-family C member 8Q09429Not Available9439807; 8955950; 9037388
ObesityATP-binding cassette sub-family C member 9Q63563Not Available9439807; 8955950; 9037388
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.0030.000415%
Drug abuse19.07.02.0100.000108%Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.0010.002490%Not Available
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.002--
Encephalopathy17.13.02.0010.000415%
Eosinophilia01.02.04.001--
Erythema23.03.06.001--Not Available
Erythropenia01.07.02.001--Not Available
Eye disorder06.08.03.001--Not Available
Feeling abnormal08.01.09.014--Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.000415%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glycosylated haemoglobin increased13.02.02.0050.000415%Not Available
Granulomatous liver disease09.01.07.001--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.0010.000415%
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis cholestatic09.01.01.002--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.000415%
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.05.02.012; 10.02.02.017; 23.06.02.005; 01.01.04.008--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.006640%
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages